Caseware UK (AP4) 2024.0.164 2024.0.164 2024-12-312024-12-31The members have not required the company to obtain an audit in accordance with section 476 of the Companies Act 2006.falseMedical Subscriptions2023-11-0100truetruefalse 11002642 2023-11-01 2024-12-31 11002642 2022-11-01 2023-10-31 11002642 2024-12-31 11002642 2023-10-31 11002642 c:Director11 2023-11-01 2024-12-31 11002642 d:CurrentFinancialInstruments 2024-12-31 11002642 d:CurrentFinancialInstruments 2023-10-31 11002642 d:CurrentFinancialInstruments d:WithinOneYear 2024-12-31 11002642 d:CurrentFinancialInstruments d:WithinOneYear 2023-10-31 11002642 d:ShareCapital 2024-12-31 11002642 d:ShareCapital 2023-10-31 11002642 d:SharePremium 2024-12-31 11002642 d:SharePremium 2023-10-31 11002642 d:CapitalRedemptionReserve 2024-12-31 11002642 d:CapitalRedemptionReserve 2023-10-31 11002642 d:MergerReserve 2024-12-31 11002642 d:MergerReserve 2023-10-31 11002642 d:RetainedEarningsAccumulatedLosses 2024-12-31 11002642 d:RetainedEarningsAccumulatedLosses 2023-10-31 11002642 c:OrdinaryShareClass1 2023-11-01 2024-12-31 11002642 c:OrdinaryShareClass1 2024-12-31 11002642 c:OrdinaryShareClass1 2023-10-31 11002642 c:FRS102 2023-11-01 2024-12-31 11002642 c:AuditExempt-NoAccountantsReport 2023-11-01 2024-12-31 11002642 c:FullAccounts 2023-11-01 2024-12-31 11002642 c:PrivateLimitedCompanyLtd 2023-11-01 2024-12-31 11002642 6 2023-11-01 2024-12-31 11002642 e:PoundSterling 2023-11-01 2024-12-31 xbrli:shares iso4217:GBP xbrli:pure

Registered number: 11002642









MAP LIFE SCIENCES LIMITED







UNAUDITED

FINANCIAL STATEMENTS

INFORMATION FOR FILING WITH THE REGISTRAR

FOR THE PERIOD ENDED 31 DECEMBER 2024

 
MAP LIFE SCIENCES LIMITED
REGISTERED NUMBER: 11002642

BALANCE SHEET
AS AT 31 DECEMBER 2024

31 December
31 December
31
October
31
October
2024
2024
2023
2023
Notes
£
£
£
£

FIXED ASSETS
  

Investments
 4 
271,318
272,418

  
271,318
272,418

CURRENT ASSETS
  

Debtors: amounts falling due within one year
 5 
835,719
383,449

Cash at bank and in hand
  
2,398
11,156

  
838,117
394,605

Creditors: amounts falling due within one year
 6 
(836,522)
(233,023)

NET CURRENT ASSETS
  
 
 
1,595
 
 
161,582

  

TOTAL ASSETS LESS CURRENT LIABILITIES BEING NET ASSETS
  
272,913
434,000


CAPITAL AND RESERVES
  

Called up share capital 
 7 
101
101

Share premium account
  
106,056
106,056

Capital redemption reserve
  
17
17

Merger reserve
  
2,001
2,001

Profit and loss account
  
164,738
325,825

SHAREHOLDERS' FUNDS
  
272,913
434,000


The Directors consider that the Company is entitled to exemption from audit under Section 477 of the Companies Act 2006 and members have not required the Company to obtain an audit for the period in question in accordance with Section 476 of the Companies Act 2006.

The Directors acknowledge their responsibilities for complying with the requirements of the Companies Act 2006 with respect to accounting records and the preparation of financial statements.

Page 1

 
MAP LIFE SCIENCES LIMITED
REGISTERED NUMBER: 11002642
    
BALANCE SHEET (CONTINUED)
AS AT 31 DECEMBER 2024

The financial statements have been prepared in accordance with the provisions applicable to companies subject to the small companies regime and in accordance with the provisions of FRS 102 Section 1A - small entities.

The financial statements have been delivered in accordance with the provisions applicable to companies subject to the small companies regime.

The Company has opted not to file the profit and loss account in accordance with provisions applicable to companies subject to the small companies' regime.

The financial statements were approved and authorised for issue by the Board of Directors and were signed on its behalf by: 





T J Collins
Director

Date: 11 December 2025

The notes on pages 3 to 6 form part of these financial statements.

Page 2

 
MAP LIFE SCIENCES LIMITED
 
 
 
NOTES TO THE FINANCIAL STATEMENTS
FOR THE PERIOD ENDED 31 DECEMBER 2024

1.


GENERAL INFORMATION

MAP Life Sciences Limited (the "Company") is a private company limited by shares and incorporated in England and Wales. Its registered office is Upper Pendrill Court, Ermine Street North, Papworth Everard, Cambridge CB23 3UY.

The current period financial statements cover the period of 14 months from 1 November 2023 to 31 December 2024. The comparative information covers a period of 12 months from 1 November 2022 to 31 October 2023.

2.ACCOUNTING POLICIES

 
2.1

BASIS OF PREPARATION OF FINANCIAL STATEMENTS

The financial statements have been prepared under the historical cost convention unless otherwise specified within these accounting policies and in accordance with FRS 102 'The Financial Reporting Standard applicable in the UK and the Republic of Ireland' and the requirements of the Companies Act 2006. The disclosure requirements of Section 1A of FRS 102 have been applied other than where additional disclosure is required to show a true and fair view.

The following principal accounting policies have been applied:

 
2.2

GOING CONCERN

The financial statements have been prepared on a going concern basis which assumes that the Company will have adequate resources to continue in operational existence for the foreseeable future.

In making their assessment the Directors have considered the Company's liquidity requirements based upon review of budgets and cash flow forecasts prepared covering a period of at least 12 months from the date of approving these financial statements as well as the ongoing support of the ultimate controlling party.

Page 3

 
MAP LIFE SCIENCES LIMITED
 
 
 
NOTES TO THE FINANCIAL STATEMENTS
FOR THE PERIOD ENDED 31 DECEMBER 2024

2.ACCOUNTING POLICIES (CONTINUED)

 
2.3

FOREIGN CURRENCY TRANSLATION

Functional and presentation currency

The Company's functional and presentational currency is Sterling.

Transactions and balances

Foreign currency transactions are translated into the functional currency using the spot exchange rates at the dates of the transactions.

At each period end foreign currency monetary items are translated using the closing rate. Non-monetary items measured at historical cost are translated using the exchange rate at the date of the transaction and non-monetary items measured at fair value are measured using the exchange rate when fair value was determined.

Foreign exchange gains and losses resulting from the settlement of transactions and from the translation at period-end exchange rates of monetary assets and liabilities denominated in foreign currencies are recognised in profit or loss except when deferred in Other Comprehensive Income as qualifying cash flow hedges.

Foreign exchange gains and losses that relate to borrowings and cash and cash equivalents are presented in the Profit and Loss Account within either 'Interest Receivable' or 'Interest Payable'. All other foreign exchange gains and losses are presented in profit or loss within 'Administrative Expenses'.

 
2.4

INVESTMENTS

Investments in subsidiary undertakings are measured at cost less accumulated impairment charges.

 
2.5

DEBTORS

Short-term debtors are measured at transaction price, less any impairment.

 
2.6

CASH AND CASH EQUIVALENTS

Cash is represented by cash in hand and deposits with financial institutions repayable without penalty on notice of not more than 24 hours. Cash equivalents are highly liquid investments that mature in no more than three months from the date of acquisition and that are readily convertible to known amounts of cash with insignificant risk of change in value.

 
2.7

CREDITORS

Short-term creditors are measured at the transaction price. Other financial liabilities are measured initially at fair value, net of transaction costs, and are measured subsequently at amortised cost using the effective interest method.


3.


EMPLOYEES

There were no employees, other than the Directors, of the Company in both the current period and the prior year, who were remunerated via other group companieswithout right of recharge. 

Page 4

 
MAP LIFE SCIENCES LIMITED
 
 
 
NOTES TO THE FINANCIAL STATEMENTS
FOR THE PERIOD ENDED 31 DECEMBER 2024

4.


FIXED ASSET INVESTMENTS








Investments in subsidiary undertakings

£



COST AND NET BOOK VALUE


At 1 November 2023
272,418


Disposals
(1,100)



At 31 December 2024
271,318




On 7 May 2024, MAP MedTech Limited was dissolved.  The corresponding intercompany creditor has also been released resulting in no gain or loss in the Profit and Loss Account.

On 14 May 2024, MAP Market Access Limited was dissolved, resulting in a loss on disposal of £100.


5.


DEBTORS

31 December
31
October
2024
2023
£
£


Amounts owed by fellow group undertakings
822,023
328,630

Other debtors
1,400
999

Prepayments and accrued income
12,296
53,820

835,719
383,449


Amounts owed by fellow group undertakings are unsecured, interest free and repayable on demand.

Page 5

 
MAP LIFE SCIENCES LIMITED
 
 
 
NOTES TO THE FINANCIAL STATEMENTS
FOR THE PERIOD ENDED 31 DECEMBER 2024

6.


CREDITORS: AMOUNTS FALLING DUE WITHIN ONE YEAR

31 December
31
October
2024
2023
£
£

Trade creditors
4,200
35,758

Amounts owed to fellow group undertakings
828,062
17,777

Other creditors
-
173,763

Accruals and deferred income
4,260
5,725

836,522
233,023


Amounts owed to fellow group undertakings are unsecured, interest free and repayable on demand.


7.


SHARE CAPITAL

31
December
31
October
2024
2023
£
£
ALLOTTED, CALLED UP AND FULLY PAID



10,084,929 (2023 - 10,084,929) Ordinary shares of £0.00001 each
101
101



8.


CONTROLLING PARTY

The immediate parent undertaking of MAP Life Sciences Limited is Mustang Bidco Limited, a company registered in England and Wales. The ultimate parent undertaking is Mustang Topco Limited, a company registered in England and Wales. 

The ultimate controlling party is Kester Capital III GP LLP, managed by Kester Capital LLP, by virtue of its controlling ownership in the shares of Mustang Topco Limited on behalf of various funds.

 
Page 6